The U.S. Food and Drug Administration is urging manufacturers of Xolair to put stronger labels on their medication because it runs the risk of a life-threatening allergic reaction. Amanda Gardner of HealthDay News reports:Sounds like putting a band-aid on a gunshot wound, doesn’t it?
The new alert for Xolair (omalizumab), marketed by Genentech Inc., draws attention to anaphylaxis as a potential side effect of the medication…If medications make you nervous, check out DiseaseProof’s Asthma archive for posts on treating asthma with superior nutrition.
… The new warning discusses the possibility of patients developing anaphylaxis after any dose of Xolair, even if there was no reaction to the first dose. Also, the reaction may occur up to 24 hours after administration of the drug.